WuXi AppTec Co Ltd
SSE:603259
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
280B CNY |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
204.8B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
152.3B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
75.9T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
35.6B CHF |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
37B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
30.6B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.3B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
22.6B USD |
Loading...
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
17.7B EUR |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
WuXi AppTec Co Ltd
Glance View
In the bustling corridors of global pharmaceuticals, WuXi AppTec Co Ltd. emerges as a vital bridge between expansive scientific potential and the practical demands of drug development. Founded in China, WuXi AppTec began its journey by transforming itself into a leading provider of R&D and manufacturing services to the pharmaceutical, biotech, and healthcare industries. With a broad portfolio that spans from the initial stages of drug discovery to the intricate processes of commercial production, WuXi AppTec offers an integrated platform to its clients. This platform allows global pharmaceutical companies, fledgling biotech firms, and even academic institutions to streamline their research initiatives, reduce development timelines, and ultimately bring therapeutic innovations to the market more efficiently. The company's business model thrives on its "one-stop-shop" approach, which is comprised of client-tailored solutions that address every stage of the drug development lifecycle. WuXi generates revenue through a variety of services, including laboratory testing, clinical trial support, and large-scale manufacturing. By leveraging its comprehensive capabilities in chemistry, biologics, and genomics, it successfully caters to a diversified clientele, ensuring sustainability through a steady stream of contract-based income. With an emphasis on advanced technologies and a global footprint that covers North America, Europe, and Asia, WuXi AppTec stands as a crucial ally to innovators ardently seeking to overcome the challenges of modern medicine by expediting the path from ‘concept’ to ‘cure’.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for WuXi AppTec Co Ltd is 30.4%, which is above its 3-year median of 27.6%.
Over the last 3 years, WuXi AppTec Co Ltd’s Operating Margin has increased from 22.8% to 30.4%. During this period, it reached a low of 22.8% on Sep 30, 2022 and a high of 30.4% on Sep 30, 2025.